Zou Gongdao, Lu Wei, Dai Xiaofen
Department of Cardiothoracic, The First Affiliated Hospital of Yangtze University No.55 Jianghan North Road, Shashi District, Jingzhou 434000, Hubei, China.
Am J Transl Res. 2023 Feb 15;15(2):1215-1222. eCollection 2023.
To explore the relationship between serum circular RNA ERBB2 (CircERBB2) levels and clinicopathological features and prognosis of patients with non-small cell lung cancer (NSCLC).
In this retrospective study, 87 patients with NSCLC (NSCLC group) and 85 patients with benign lung disease (benign lung disease group) in the First Affiliated Hospital of Yangtze University from March 2016 to February 2019 were enrolled; in addition, another 87 healthy subjects were selected as the control group. Serum levels of CircERBB2, cytokeratin 19 fragment (CYFRA21-1) and carcinoembryonic antigen (CEA) in each group were detected, and their relationship with the prognosis of NSCLC patients as well as their diagnostic value was analyzed. The serum CircERBB2 levels in NSCLC patients with different clinicopathological characteristics were compared, and the correlation of serum level of CircERBB2 with CircERBB2 as well as CYFRA21-1 was analyzed.
The serum CircERBB2, CYFRA21-1 and CEA levels in the control group, benign lung disease group and NSCLC group were gradually increased (<0.05). In the NSCLC group, serum CircERBB2 level was correlated with lymph node metastasis, tumor diameter and TNM stage (<0.05). The areas under the curve (AUCs) of serum CircERBB2, CYFRA21-1, and CEA in diagnosing NSCLC were 0.871, 0.693, and 0.861, with cut-off values of 2.27, 4.45 ng/mL, and 18.49 ng/mL, respectively. The sensitivity was 80.5%, 65.5%, 78.2%, the specificity was 87.1%, 74.1%, 88.2%, respectively. The AUC and sensitivity of CircERBB2 combined with CEA in diagnosing NSCLC was 0.938 and 94.3%, respectively. The serum CircERBB2 level was positively correlated with CYFRA21-1 and CEA in the NSCLC group (<0.05); and the levels of the above three serum indexes were significantly higher in the death group than those in the survival group (all <0.05). The 36-month cumulative survival rate of patients in the CircERBB2 low expression group was longer than that in the CircERBB2 high expression group (<0.05).
Serum CircERBB2 is highly expressed in NSCLC patients, and closely related to disease progression, so it has good prognostic value.
探讨血清环状RNA ERBB2（CircERBB2）水平与非小细胞肺癌（NSCLC）患者临床病理特征及预后的关系。
本回顾性研究纳入了2016年3月至2019年2月在长江大学附属第一医院就诊的87例NSCLC患者（NSCLC组）和85例良性肺疾病患者（良性肺疾病组）；此外，另选87例健康受试者作为对照组。检测各组血清CircERBB2、细胞角蛋白19片段（CYFRA21-1）和癌胚抗原（CEA）水平，并分析其与NSCLC患者预后的关系及其诊断价值。比较不同临床病理特征的NSCLC患者血清CircERBB2水平，分析血清CircERBB2水平与CircERBB2以及CYFRA21-1的相关性。
对照组、良性肺疾病组和NSCLC组血清CircERBB2、CYFRA21-1和CEA水平逐渐升高（P<0.05）。在NSCLC组中，血清CircERBB2水平与淋巴结转移、肿瘤直径和TNM分期相关（P<0.05）。血清CircERBB2、CYFRA21-1和CEA诊断NSCLC的曲线下面积（AUC）分别为0.871、0.693和0.861，截断值分别为2.27、4.45 ng/mL和18.49 ng/mL。敏感性分别为80.5%、65.5%、78.2%，特异性分别为87.1%、74.1%、88.2%。CircERBB2联合CEA诊断NSCLC的AUC和敏感性分别为0.938和94.3%。NSCLC组血清CircERBB2水平与CYFRA21-1和CEA呈正相关（P<0.05）；死亡组上述三项血清指标水平均显著高于生存组（均P<0.05）。CircERBB2低表达组患者的36个月累积生存率长于CircERBB2高表达组（P<0.05）。
血清CircERBB2在NSCLC患者中高表达，与疾病进展密切相关，具有良好的预后价值。
